AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03120624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Description: Given IV
Study NCT01987843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03470896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preanesthesia teleconsultation
Description: According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
Study NCT03120624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT03120624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sodium Pertechnetate
Description: Given IV
Study NCT03120624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo mouth rinse, buccal swab, urine, and blood sample collection
Study NCT05037396 — intervention group
Intervention type: DRUG
Intervention: Brolucizumab
Description: Participants received brolucizumab injection during the index period
Study NCT04274738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Study NCT04274738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules will be administered per dose and schedule specified in the arm.
Study NCT04471428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.
Study NCT04471428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
Study NCT04471428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
Study NCT03903185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir / Sofosbuvir Oral Product
Description: 45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
Study NCT02270125 — intervention group
Intervention type: PROCEDURE
Intervention: Mucotomy
Description: Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
Study NCT03849300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic walking exercise program group 1
Description: 12 week aquatic walking exercise program
Study NCT03849300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic walking exercise program group 2
Description: 12 week aquatic walking exercise program
Study NCT03849300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based walking exercise group
Description: 12 week land-based walking exercise program
Study NCT04327349 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Convalescent Plasma
Description: Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
Study NCT05618717 — intervention group
Intervention type: DEVICE
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation using irrigated ablation catheter
Study NCT04528368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
Study NCT00860522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JVRS-100
Description: Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
Study NCT00860522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JVRS-100
Description: Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
Study NCT04273854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®
Description: The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
Study NCT04430894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity
Study NCT03470896 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: preanesthesia traditional consultation
Description: According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
Study NCT03470896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preanesthesia traditional consultation
Description: According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
Study NCT03782688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FFRCT planner
Description: Non-invasive post-PCI fractional flow reserve prediction
Study NCT03556046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-Girentuximab
Description: Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
Study NCT06596382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol rich-vitamin E
Description: Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome
Study NCT06596382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replicate for tocotrienol rich-vitamin E without any active ingredients
Study NCT02069145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28 with Sorafenib
Study NCT00424632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03814735
Description: 1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
Study NCT04130594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac
Description: a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
Study NCT04130594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00018174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT00018174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral group smoking cessation treatment
Study NCT00018174 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral group smoking cessation treatment
Study NCT00018174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01827072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study NCT04223856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
Study NCT04223856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion on Day 1 of every 3-week cycle
Study NCT03312881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: quantitative sensory testing
Description: multiple modality testing of generalized and localized changes in somatosensory perception
Study NCT03312881 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuroimaging
Description: magnetic resonance imaging (MRI)
Study NCT03312881 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcome Measures
Description: neuropathic pain screening tool; validated questionnaires
Study NCT02384239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given orally (PO)
Study NCT02384239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given orally (PO)
Study NCT02384239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given by intramuscular (IM) injection.
Study NCT04223856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: administered as IV infusion on Day 1 of each 3-week cycle
Study NCT04223856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
Study NCT04223856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion on Days 1 and 8 of every 3 week cycle
Study NCT03492307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)
Description: A weight-based flow for HFNC.
Study NCT03492307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Flow for HFNC (Maximum 8L/minute)
Description: Maximum flow of 8L/minute.
Study NCT03910335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LSS Screen
Description: Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
Study NCT00938925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nail lacquer plus aggressive debridement
Description: Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
Study NCT00938925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nail lacquer alone
Description: Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
Study NCT03886038 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertugliflozin
Description: Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
Study NCT02033889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
Study NCT02033889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Glimepiride
Description: Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
Study NCT02033889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
Study NCT02033889 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Basal Insulin
Description: Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin >=1500 mg/day, orally, once a day
Study NCT04430894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: * Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  -- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity
Study NCT04430894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity
Study NCT04430894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
Study NCT02397902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat dairy
Description: Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
Study NCT02397902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based
Description: Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
Study NCT04578691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatase Spine Surgery Navigation System
Description: using navigation system in pedicle screw placement in spine surgery
Study NCT04578691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Stealthstation S7 Treatment Guidance System
Description: using navigation system in pedicle screw placement in spine surgery
Study NCT01328223 — intervention group
Intervention type: RADIATION
Intervention: sorafenib and radiotherapy for hepatocellular carcinoma
Description: Concurrent and maintenance sorafenib 400mg twice daily
Study NCT02275351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04554
Description: Topical solution, applied once a day
Study NCT02275351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical solution, applied once a day
Study NCT02001467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based training
Study NCT01500434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
Study NCT01500434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Study NCT01500434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study NCT01446302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Double meal
Description: A standardized meal is served 1 h after start of HD and 1 h after end of HD.
Study NCT02500589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral mood management
Description: The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
Study NCT02500589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health education
Description: In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information.
Study NCT01881477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinetics modalities
Description: The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk.
Study NCT02033889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin >=1500 mg/day, orally, once a day
Study NCT00623220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N2O
Description: EMONO
Study NCT03808181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ChloraSolv
Description: Weekly application of ChloraSolv for 6 weeks
Study NCT00852059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (Medikinet®)
Description: Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
Study NCT00852059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release methylphenidate (Medikinet retard®)
Description: Treatment: methylphenidate applied with breakfast(once daily), extended release
Study NCT00623220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: oxygen
Study NCT02569697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo gel